Back to Search
Start Over
Trends in survival for teenagers and young adults with cancer in the UK 1992-2006.
- Source :
-
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2015 Sep; Vol. 51 (14), pp. 2039-48. Date of Electronic Publication: 2015 Jul 25. - Publication Year :
- 2015
-
Abstract
- Background: Although relatively rare, cancer in teenagers and young adults (TYA) is the most common disease-related cause of death and makes a major contribution to years of life lost in this age group. There is a growing awareness of the distinctive needs of this age group and drive for greater understanding of how outcomes can be improved. We present here the latest TYA survival trends data for the United Kingdom (UK).<br />Methods: Using national cancer registry data, we calculated five-year relative survival for all 15-24 year olds diagnosed with cancer or a borderline/benign CNS tumour in the UK during the periods 1992-1996, 1997-2001 and 2002-2006. We analysed trends in survival for all cancers combined and for eighteen specified groups that together represent the majority of TYA cancers. We compared our data with published data for Europe, North America and Australia.<br />Results: Five-year survival for all cancers combined increased from 75.5% in 1992-1996 to 82.2% in 2002-2006 (P<0.001). Statistically significant improvements were seen for all disease groups except osteosarcoma, rhabdomyosarcoma, non-gonadal and ovarian germ cell tumours and ovarian and thyroid carcinomas. During the earliest time period, females had significantly better survival than males for five of the twelve non-gender-specific disease groups. By the latest period, only melanomas and non-rhabdomyosarcoma soft tissue sarcomas had differential survival by gender. Survival in the UK for the most recent period was generally similar to other comparable countries.<br />Conclusion: Five-year survival has improved considerably in the UK for most cancer types. For some disease groups, there has been little progress, either because survival already approaches 100% (e.g. thyroid carcinomas) or, more worryingly for some cancers with poor outcomes, because they remain resistant to existing therapy (e.g. rhabdomyosarcoma). In addition, for a number of specific cancer types and for cancer as a whole males continue to have worse outcomes than females.<br /> (Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Subjects :
- Adolescent
Age Distribution
Age Factors
Australia epidemiology
Female
Humans
Male
Neoplasms diagnosis
Neoplasms mortality
Neoplasms therapy
North America epidemiology
Registries
Risk Factors
Sex Distribution
Sex Factors
Time Factors
Treatment Outcome
United Kingdom epidemiology
Young Adult
Neoplasms epidemiology
Survivors statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0852
- Volume :
- 51
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Publication Type :
- Academic Journal
- Accession number :
- 26219688
- Full Text :
- https://doi.org/10.1016/j.ejca.2015.06.112